RankingsPricing
  1. US-listed companies
  2. Intra-Cellular Therapies, Inc.
  3. Financials
  4. Return on equity (%)

Intra-Cellular Therapies, Inc.ITCI

Market cap
$13.4B
P/E ratio
SummaryFinancials
Period EndReturn on equity (%) (Million USD)YoY (%)
Dec 31, 2024-8.6-61.68%
Dec 31, 2023-22.4-53.08%
Dec 31, 2022-47.7-9.74%
Dec 31, 2021-52.9-0.81%
Dec 31, 2020-53.3-7.50%
Dec 31, 2019-57.6+43.40%
Dec 31, 2018-40.2+70.54%
Dec 31, 2017-23.6-13.83%
Dec 31, 2016-27.3-22.15%
Dec 31, 2015-35.1-12.94%
Dec 31, 2014-40.3

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)